Article (Scientific journals)
Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers ans frailty
Arden, Nigel; Richette, Pascal; Cooper, Cyrus et al.
2015In Drugs and Aging, 32, p. 529-535
Peer Reviewed verified by ORBi
 

Files


Full Text
Can We Identify Patients with High Risk of Osteoarthritis.pdf
Publisher postprint (547.85 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Osteoarthritis (OA), a disease affecting different patient phenotypes, appears as an optimal candidate for personalized healthcare. The aim of the discussions of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group was to explore the value of markers of different sources in defining different phenotypes of patients with OA. The ESCEO organized a series of meetings to explore the possibility of identifying patients who would most benefit from treatment for OA, on the basis of recent data and expert opinion. In the first meeting, patient phenotypes were identified according to the number of affected joints, biomechanical factors, and the presence of lesions in the subchondral bone. In the second meeting, summarized in the present article, the working group explored other markers involved in OA. Profiles of patients may be defined according to their level of pain, functional limitation, and presence of coexistent chronic conditions including frailty status. A considerable amount of data suggests that magnetic resonance imaging may also assist in delineating different phenotypes of patients with OA. Among multiple biochemical biomarkers identified, none is sufficiently validated and recognized to identify patients who should be treated. Considerable efforts are also being made to identify genetic and epigenetic factors involved in OA, but results are still limited. The many potential biomarkers that could be used as potential stratifiers are promising, but more research is needed to characterize and qualify the existing biomarkers and to identify new candidates.
Disciplines :
General & internal medicine
Author, co-author :
Arden, Nigel
Richette, Pascal
Cooper, Cyrus
Bruyère, Olivier  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Abadie, Eric
Branco, Jaime
Brandi, Maria-Luisa
Berenbaum, Francis
Clerc, Cécile
Dennison, Elaine
Devogelaer, Jean-Pierre
Hochberg, Marc
D'Hooghe, Pieter
Herrero-Baumont, Gabriel
Kanis, John A.
Laslop, Andrea
Leblanc, Véronique
Maggi, Stefania
Mautone, Giuseppe
Pelletier, Jean-Pierre
Petit-Dop, Florence
Reiter-Niesert, Suzanne
Rizzoli, René
Rovati, Lucio
Messi, Eleonora Tajana
Tsouderos, Yannis
Martel-Pelletier, Johanne
Reginster, Jean-Yves  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
More authors (18 more) Less
Language :
English
Title :
Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers ans frailty
Publication date :
2015
Journal title :
Drugs and Aging
ISSN :
1170-229X
eISSN :
1179-1969
Publisher :
Adis International, Auckland, New Zealand
Volume :
32
Pages :
529-535
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 10 September 2015

Statistics


Number of views
56 (7 by ULiège)
Number of downloads
2 (2 by ULiège)

Scopus citations®
 
30
Scopus citations®
without self-citations
25
OpenCitations
 
23

Bibliography


Similar publications



Contact ORBi